دورية أكاديمية
أعرض في EDS

Numbers of prenatal cell-free DNA screens performed: Results of a 2022 CAP exercise.

التفاصيل البيبلوغرافية
العنوان: Numbers of prenatal cell-free DNA screens performed: Results of a 2022 CAP exercise.
المؤلفون: Palomaki GE; Department of Pathology and Laboratory Medicine, Alpert Medical School at Brown University, Women & Infants Hospital of RI, Providence, Rhode Island, USA., Wyatt P; Esoterix Genetic Laboratories, Santa Fe, New Mexico, USA., Rowsey R; Division of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA., Cacheris PM; Sequenom Laboratories, San Diego, California, USA., Lepage N; Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada., Natowicz MR; Pathology and Laboratory Medicine, Genomic Medicine, Neurology and Pediatrics Institutes, Cleveland Clinic, Cleveland, Ohio, USA., Long T; Department of Biostatistics, College of American Pathologists, Northfield, Illinois, USA., Moyer AM; Division of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
المصدر: Prenatal diagnosis [Prenat Diagn] 2024 Jul; Vol. 44 (8), pp. 946-952. Date of Electronic Publication: 2024 Apr 15.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Wiley Country of Publication: England NLM ID: 8106540 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0223 (Electronic) Linking ISSN: 01973851 NLM ISO Abbreviation: Prenat Diagn Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Chichester, [Sussex]; New York : Wiley, c1981-
مواضيع طبية MeSH: Cell-Free Nucleic Acids*/analysis , Cell-Free Nucleic Acids*/blood , Noninvasive Prenatal Testing*/methods , Noninvasive Prenatal Testing*/statistics & numerical data, Humans ; Female ; Pregnancy ; Prenatal Diagnosis/methods ; Prenatal Diagnosis/statistics & numerical data ; Trisomy/diagnosis ; Trisomy/genetics ; Maternal Serum Screening Tests/statistics & numerical data ; Maternal Serum Screening Tests/methods
مستخلص: Objective: Determine current analytical methods and number of cell-free (cf) DNA prenatal screening tests performed for common trisomies.
Methods: The College of American Pathologists 2022-B Noninvasive Prenatal Testing exercise was distributed in December 2022 to 93 participants in 22 countries. Supplemental questions included the number of tests performed in a recent month and the proportion of samples originating outside the United States (US).
Results: Eighty-three participants from three continents returned results; 74 (89%) were suitable for the analyses. Nine manufacturer/platform combinations were identified, most commonly Illumina/Nextseq (55%). The most common methodology was whole genome sequencing (76%). Annualized cfDNA tests were 2.80 million, with Asian, European and North American participants representing 10.6%, 6.5% and 82.9% of tests, respectively. When restricted to US in-country tests, the annualized rate was 2.18 million, with four of 20 participants testing 79.2%. Among 73 respondents, 63 (86%) were for-profit, eight (11%) were non-profit academic or government supported and the remaining two included hospital-based and private non-profit. Eighteen (25%) supported relevant academic training.
Conclusion: In 2011, screening for common trisomies was based on serum/ultrasound markers with an estimated 2.96 million US pregnancies screened in 131 laboratories. In 2022, cfDNA-based screening was offered by 20 laboratories testing 2.18 million US pregnancies.
(© 2024 John Wiley & Sons Ltd.)
References: Rink BD, Norton ME. Screening for fetal aneuploidy. Semin Perinatol. 2016;40(1):35‐43. https://doi.org/10.1053/j.semperi.2015.11.006.
Cuckle H, Maymon R. Development of prenatal screening‐‐A historical overview. Semin Perinatol. 2016;40(1):12‐22. https://doi.org/10.1053/j.semperi.2015.11.003.
Steele MW, Breg WR, Jr. Chromosome analysis of human amniotic‐fluid cells. Lancet. 1966;1(7434):383‐385.
Wald NJ, Cuckle H, Brock JH, Peto R, Polani PE, Woodford FP. Maternal serum‐alpha‐fetoprotein measurement in antenatal screening for anencephaly and spina bifida in early pregnancy. Report of U.K. collaborative study on alpha‐fetoprotein in relation to neural‐tube defects. Lancet. 1977;1(8026):1323‐1332.
Merkatz IR, Nitowsky HM, Macri JN, Johnson WE. An association between low maternal serum alpha‐fetoprotein and fetal chromosomal abnormalities. Am J Obstet Gynecol. 1984;148(7):886‐894. https://doi.org/10.1016/0002‐9378(84)90530‐1.
Cuckle HS, Wald NJ, Lindenbaum RH. Maternal serum alpha‐fetoprotein measurement: a screening test for Down syndrome. Lancet. 1984;1(8383):926‐929. https://doi.org/10.1016/s0140‐6736(84)92389‐4.
Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). J Med Screen. 2003;10(2):56‐104. https://doi.org/10.1177/096914130301000202.
Palomaki GE, Knight GJ, McCarthy J, Haddow JE, Eckfeldt JH. Maternal serum screening for fetal Down syndrome in the United States: a 1992 survey. Am J Obstet Gynecol. 1993;169(6):1558‐1562. https://doi.org/10.1016/0002‐9378(93)90436‐m.
Palomaki GE, Knight GJ, McCarthy JE, Haddow JE, donhowe JM. Maternal serum screening for Down syndrome in the United States: a 1995 survey. Am J Obstet Gynecol. 1997;176(5):1046‐1051. https://doi.org/10.1016/s0002‐9378(97)70400‐9.
Palomaki GE, Ashwood ER, Best RG, Lambert‐Messerlian G, Knight GJ. Is maternal plasma DNA testing impacting serum‐based screening for aneuploidy in the United States? Genet Med. 2015;17(11):897‐900. https://doi.org/10.1038/gim.2015.39.
Lepage N, Wyatt P, Ashwood ER, Best RG, Long T, Palomaki GE. Prenatal serum screening for Down syndrome and neural tube defects in the United States: changes in utilization patterns from 2012 to 2020. J Med Screen. 2021;28(4):405‐410. https://doi.org/10.1177/09691413211031610.
Palomaki GE, Wyatt P, Best RG, et al. Assessment of laboratories offering cell‐free (cf) DNA screening for Down syndrome: results of the 2018 College of American Pathology External Educational Exercises. Genet Med. 2020;22(4):777‐784. https://doi.org/10.1038/s41436‐019‐0718‐4.
Huang T, Gibbons C, Rashid S, et al. Prenatal screening for trisomy 21: a comparative performance and cost analysis of different screening strategies. BMC Pregnancy Childbirth. 2020;20(1):713. https://doi.org/10.1186/s12884‐020‐03394‐w.
Hamilton BEMJ, Osterman MJK. Vital Statistics Rapid Release; No. 28. National Center for Health Statistics; 2023. https://doi.org/10.15620/cdc:127052.
Creswell L, Doddy F, Manning C, et al. Cell free DNA screening for fetal aneuploidy in Ireland: an observational study of outcomes following insufficient fetal fraction. Eur J Obstet Gynecol Reprod Biol. 2023;290:143‐149. https://doi.org/10.1016/j.ejogrb.2023.09.023.
Palomaki GE, Kloza EM. Prenatal cell‐free DNA screening test failures: a systematic review of failure rates, risks of Down syndrome, and impact of repeat testing. Genet Med. 2018;20(11):1312‐1323. https://doi.org/10.1038/gim.2018.22.
ACOG Practice Bulletin. No. 200: early pregnancy loss. Obstet Gynecol. 2018;132(5):e197‐e207.
Centers for Disease Control and PreventionNational Center for Health Statistics. National vital statistics system, natality on CDC WONDER online database. Data are from the natality records 2016‐2021, as compiled from data provided by the 57 vital statistics jurisdictions through the vital statistics cooperative program. Accessed August 30, 2023. http://wonder.cdc.gov/natality‐expanded‐current.html.
Palomaki GE, Kloza EM, Lambert‐Messerlian GM, et al. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med. 2011;13(11):913‐920. https://doi.org/10.1097/gim.0b013e3182368a0e.
Palomaki GE, Knight GJ, Ashwood ER, Best RG, Haddow JE. Screening for down syndrome in the United States: results of surveys in 2011 and 2012. Arch Pathol Lab Med. 2013;137(7):921‐926. https://doi.org/10.5858/arpa.2012‐0319‐cp.
Strom CM. Changing trends in laboratory testing in the United States: a personal, historical perspective. Clin Lab Med. 2012;32(4):651‐664. https://doi.org/10.1016/j.cll.2012.07.003.
Hofgärtner WT, Tait JF. Characteristics of clinical molecular‐genetic testing laboratories in the United States. Clin Chem. 1999;45(8 Pt 1):1288‐1290. https://doi.org/10.1093/clinchem/45.8.1288.
Check W. Going the way of fewer, larger labs. In: CAP TODAY. Vol 8; 1994.
Devereaux KA, Souers RJ, Merker JD, et al. Clinical testing for tumor cell‐free DNA: College of American Pathologists proficiency programs reveal practice trends. Arch Pathol Lab Med. 2023;147(4):425‐433. https://doi.org/10.5858/arpa.2021‐0585‐cp.
Murdoch B, Ravitsky V, Ogbogu U, et al. Non‐invasive prenatal testing and the unveiling of an impaired translation process. J Obstet Gynaecol Can. 2017;39(1):10‐17. https://doi.org/10.1016/j.jogc.2016.09.004.
Wolff ND, Wolff JA. A commentary on commercial genetic testing and the future of the genetic counseling profession. J Genet Counsel. 2018;27(3):521‐527. https://doi.org/10.1007/s10897‐018‐0244‐6.
Milunsky A. Threatened survival of academic‐based genetic laboratory services. Am J Hum Genet. 1992;50(3):643‐645.
المشرفين على المادة: 0 (Cell-Free Nucleic Acids)
تواريخ الأحداث: Date Created: 20240415 Date Completed: 20240703 Latest Revision: 20240725
رمز التحديث: 20240726
DOI: 10.1002/pd.6574
PMID: 38622635
قاعدة البيانات: MEDLINE
الوصف
تدمد:1097-0223
DOI:10.1002/pd.6574